Mylan Announces Senior Management and Board Appointments.

Business/Technology Editors & Medical Writers

PITTSBURGH--(BUSINESS WIRE)--March 5, 2002

Mylan Laboratories Inc. (NYSE:MYL) today announced that it has named Edward J. Borkowski as Chief Financial Officer of the company.

Mr. Borkowski joins Mylan from Pharmacia Corporation (NYSE:PHA) where he was most recently Vice President, Global Finance and Information Technology. Previously, Mr. Borkowski served in a variety of finance positions at American Home Products (NYSE:AHP) from 1992-1999, rising to the level of Comptroller for the Cyanamid Agricultural Products Division.

"Ed brings highly relevant pharmaceutical finance expertise to Mylan," said Chairman and Chief Executive Officer Milan Puskar. "His experience as both an auditor and finance executive at large-capitalization healthcare companies make him an ideal colleague to join Mylan's senior management team."

Mr. Borkowski is a Certified Public Accountant and began his career with Arthur Andersen in 1984. He received a BS in Economics and Political Science from Allegheny College and earned his MBA in Finance and Accounting from Rutgers University.

Mylan also today named Stuart A. Williams as Chief Legal Officer of Mylan Laboratories, effective March 1, 2002. He joins Mylan from the Pittsburgh law firm DKW Group, where he served as legal counsel to Mylan. Mr. Williams holds a BA, with highest distinction, from Pennsylvania State University and his JD from Georgetown University.

"Stu became a member of our board in July 2001, and we are pleased that he has agreed to join the company in an operating role," said Milan Puskar. "He has served as outside counsel to the company since 1995, and his legal expertise is greatly valued by Mylan."

Mylan today named Dr. Randall L. (Pete) Vanderveen to its Board of Directors, effective March 1, 2002. Dr. Vanderveen brings academic knowledge, clinical experience and administrative expertise to the Board.

"Pete is one of the most experienced and respected authorities in the appropriate use of medications, and we are delighted that he has agreed to join our Board," said Puskar.

Dr. Vanderveen serves as Dean of the School of Pharmacy and the Graduate School of Pharmaceutical Sciences at Duquesne University.

Dr. Vanderveen holds several advanced degrees. In 1976, he received his Master of Science degree in Clinical Pharmacy from Purdue University where he had earned his Bachelor of Science in Pharmacy two years earlier. In 1987, he earned his Ph.D. in University Administration from Michigan State University. In 1998, Dr. Vanderveen completed The Fuqua School of Business Leadership Development Program at Duke University.

Mylan further said today that Robert J. Coury, who joined Mylan's Board in February 2002, has been named Vice Chairman of the Board, effective March 1, 2002.

Mylan Laboratories Inc. is a leading pharmaceutical company that develops, manufactures and markets generic and proprietary prescription pharmaceutical products. The Company markets an extensive line of generic products through three business units, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and UDL Laboratories, Inc. and branded products through its Bertek Pharmaceuticals Inc. subsidiary. For more information, visit www.mylan.com.